JP2018172344A - B型ボツリヌス毒素を用いたレイノー現象の治療 - Google Patents
B型ボツリヌス毒素を用いたレイノー現象の治療 Download PDFInfo
- Publication number
- JP2018172344A JP2018172344A JP2017072001A JP2017072001A JP2018172344A JP 2018172344 A JP2018172344 A JP 2018172344A JP 2017072001 A JP2017072001 A JP 2017072001A JP 2017072001 A JP2017072001 A JP 2017072001A JP 2018172344 A JP2018172344 A JP 2018172344A
- Authority
- JP
- Japan
- Prior art keywords
- raynaud
- phenomenon
- botulinum toxin
- toxin type
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
た。冷水負荷直後から20分後の皮膚温度の回復度は、投与前と比べて、4週間後では有意に上昇していた。指尖部潰瘍(5例)は12週間後までに全て上皮化した。全ての症例で筋力低下や疼痛などの副作用はみられなかった。この自主研究によって、A型ボツリヌス毒素10単位局所注入の安全性や有効性を確認することができた(非特許文献7)。
また、B型ボツリヌス毒素の使用量(単位)はA:B=1:20〜40ぐらいの比率で使用すると、ほぼ同等の効果を有すると考えられている(非特許文献8)が、レイノー現象に対する治療効果を示す濃度は不明である。
レイノー現象は手指の色調変化などにより臨床的に診断でき、その重篤度はレイノースコアなどによって診断できる。
本発明では、ボツリヌス菌によって産生される分子量約150kDaのB型ボツリヌス毒素を使用可能であるが、非毒素タンパク質とB型ボツリヌス毒素とタンパク質との複合体(分子量約500kDa)を使用することもできる。
B型ボツリヌス毒素はボツリヌス菌から精製することによって得られたものでもよいし、遺伝子組み換えで生産されたものでもよい。また、B型ボツリヌス毒素はレイノー現象治療効果を有する限り、部分タンパク質や変異体であってもよい。
B型ボツリヌス毒素は商業的に入手し得る製剤を使用することもでき、例えば、商品名ナーブロック(エーザイ)を使用することもできる。
Claims (4)
- B型ボツリヌス毒素を有効成分として含むレイノー現象治療用医薬組成物。
- 注射剤である、請求項1に記載のレイノー現象治療用医薬組成物。
- 患部に局所投与される、請求項1または2に記載のレイノー現象治療用医薬組成物。
- B型ボツリヌス毒素の投与量が1部位あたり200〜400単位である、請求項3に記載のレイノー現象治療用医薬組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017072001A JP6450999B2 (ja) | 2017-03-31 | 2017-03-31 | B型ボツリヌス毒素を用いたレイノー現象の治療 |
US15/941,089 US10478478B2 (en) | 2017-03-31 | 2018-03-30 | Treatment of Raynaud's phenomenon using botulinum toxin type B |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017072001A JP6450999B2 (ja) | 2017-03-31 | 2017-03-31 | B型ボツリヌス毒素を用いたレイノー現象の治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018172344A true JP2018172344A (ja) | 2018-11-08 |
JP6450999B2 JP6450999B2 (ja) | 2019-01-16 |
Family
ID=63672750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017072001A Active JP6450999B2 (ja) | 2017-03-31 | 2017-03-31 | B型ボツリヌス毒素を用いたレイノー現象の治療 |
Country Status (2)
Country | Link |
---|---|
US (1) | US10478478B2 (ja) |
JP (1) | JP6450999B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6450999B2 (ja) * | 2017-03-31 | 2019-01-16 | 国立大学法人群馬大学 | B型ボツリヌス毒素を用いたレイノー現象の治療 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007517890A (ja) * | 2004-01-08 | 2007-07-05 | アラーガン、インコーポレイテッド | 血管障害の処置方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201604530SA (en) * | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
WO2009158687A1 (en) * | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
US20120328549A1 (en) * | 2011-01-24 | 2012-12-27 | Anterios, Inc. | Oil compositions |
JP2014503587A (ja) * | 2011-01-24 | 2014-02-13 | アンテリオス, インコーポレイテッド | 界面活性剤組成物 |
WO2012103040A1 (en) * | 2011-01-24 | 2012-08-02 | Anterios, Inc. | Paraben compositions |
AU2015252947B2 (en) * | 2014-05-01 | 2020-07-09 | Anterios, Inc. | Demonstrable efficacy across or within patient populations |
JP6450999B2 (ja) * | 2017-03-31 | 2019-01-16 | 国立大学法人群馬大学 | B型ボツリヌス毒素を用いたレイノー現象の治療 |
-
2017
- 2017-03-31 JP JP2017072001A patent/JP6450999B2/ja active Active
-
2018
- 2018-03-30 US US15/941,089 patent/US10478478B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007517890A (ja) * | 2004-01-08 | 2007-07-05 | アラーガン、インコーポレイテッド | 血管障害の処置方法 |
Non-Patent Citations (2)
Title |
---|
JOURNAL OF DERMATOLOGY, vol. Vol.43, JPN6018032215, 2016, pages 56 - 62 * |
PATIL, S. ET AL.: "Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States", CURR. PAIN HEADACHE REP., vol. 20:15, JPN6018032217, 2016, pages 8pages * |
Also Published As
Publication number | Publication date |
---|---|
US20180280484A1 (en) | 2018-10-04 |
US10478478B2 (en) | 2019-11-19 |
JP6450999B2 (ja) | 2019-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Campochiaro et al. | Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial | |
EP1086702B1 (en) | Presynaptic neurotoxins for treatment of migraine headache | |
JP4602762B2 (ja) | 持続勃起症を処置するためのボツリヌス毒素 | |
KR101135486B1 (ko) | 보툴리눔 에이형 독소의 액상제품 | |
US9050337B2 (en) | Method for treating atrophic skin scars using a mixture of botulinum toxin and air | |
JP6450999B2 (ja) | B型ボツリヌス毒素を用いたレイノー現象の治療 | |
Ezz et al. | Ultra-low-dose naloxone added to fentanyl and lidocaine for peribulbar anesthesia: a randomized controlled trial | |
JP3502574B2 (ja) | 眼感染症治療用眼軟膏剤 | |
EP1491205A1 (en) | Remedy for hypermyotonia | |
KR20130106557A (ko) | 보툴리눔 에이형 독소의 액상제품 | |
Lindstedt et al. | A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results | |
US20180125951A1 (en) | Methods for alleviating histamine-independent pruritus using neurotoxins | |
KR20200006587A (ko) | 경부 근긴장이상증의 치료 방법 | |
López-Cano et al. | Chemical component separation using botulinum toxin | |
Ng et al. | Treatment of experimental Staphylococcus epidermidis endophthalmitis with oral trovafloxacin | |
US20140005597A1 (en) | Kit and method for use in administering therapeutic botulinum toxin (botox) | |
Wilson | Streptomycin in Non-tuberculous Infections | |
Mathieu et al. | Necrotizing soft tissue infections | |
Mohankumar et al. | Role of hyaluronidase as an adjuvant in local anesthesia for cataract surgery | |
Nicol et al. | Pharmacology for the interventional pain physician | |
Kung et al. | Has subcutaneous botulinum toxin A been prioritised for a painful skin in an elderly patient with post-herpetic neuralgia? | |
Jabbari | Botulinum Toxin Therapy for Neuropathic Pain (NP) | |
Poenaru et al. | Pain Modulation in Chronic Musculoskeletal Disorders: Botulinum Toxin, a Descriptive Analysis. Biomedicines 2023, 11, 1888 | |
Elmas et al. | Tardive torticollis, botulinum treatment: a case report | |
Labelle | Therapy of the eye |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180828 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181113 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6450999 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |